Mitomycin-c Application for PRK
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01504282|
Recruitment Status : Completed
First Posted : January 5, 2012
Last Update Posted : January 5, 2012
|Condition or disease||Intervention/treatment||Phase|
|Myopia||Drug: mitomycin-C Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Mitomycin-c Application for Photorefractive Keratectomy|
Active Comparator: MMC group
One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
Placebo Comparator: BSS group
One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
balanced salt solution (BSS)
- Central corneal endothelial cell density (ECD) 6 months after the PRK [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01504282
|Iran, Islamic Republic of|
|Ophthalmic Research Center|
|Tehran, Iran, Islamic Republic of, 16666|